Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine

Journal of Leukocyte Biology

Volumn 72, Issue 1, 2002, Pages 183-191

  Ludwig, Andreas ^a   Schiemann, Florian ^a   Mentlein, Rolf ^b   Lindner, Buko ^a   Brandt, Ernst ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b Kiel and Lungen Clinic Grosshansdorf   (Germany)

Author keywords

Calcium transients; Chemotaxis; Inactivation; Interferon inducible T cell chemoattractant; Internalization; Receptor

Indexed keywords

ALPHA CHEMOKINE; CALCIUM; CHEMOATTRACTANT; CHEMOKINE RECEPTOR CXCR3; DIPEPTIDYL PEPTIDASE IV; INTERLEUKIN 2; PROTEIN CXCL11; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM TRANSPORT; CHEMOTAXIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE;

ANTIGENS, CD26; CALCIUM; CELLS, CULTURED; CHEMOKINES, CXC; CHEMOTAXIS, LEUKOCYTE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; KINETICS; LYMPHOCYTE ACTIVATION; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES;

EID: 0036659179     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Van Damme, J., Struyf, S., Wuyts, A., Van Collie, E., Menten, P., Schols, D., Sozzani, S., De Meester, I., Proost, P. (1999) The role of CD26/DPP IV in chemokine processing. Chem. Immunol. 72, 42-56.
2. De Meester, I., Korom, S., Van Damme, J., Scharpé, S. (1999) CD26, let it cut or cut it down. Immunol. Today 20, 367-375.
3. Mentlein, R. (1999) Dipeptidyl peptidase IV (CD 26) - role in the inactivation of regulatory peptides. Regul. Pept. 85, 9-24.
4. Mentlein, R., Heymann, E., Scholz, W., Feller, A. C., Flad, H-D. (1984) Dipeptidyl peptidase IV as a new surface marker for a subpopulation of human T-lymphocytes. Cell. Immunol. 89, 11-19.
5. Ulmer, A. J., Mattern, T., Feller, A. C., Heymann, E., Flad, H-D. (1990) CD26 antigen is a surface dipeptidyl peptidase (DPP IV) as characterized by monoclonal antibodies clone TII-19-4-7 and 4EL1C7. Scand. J. Immunol. 31, 429-435.
6. Hegen, M., Niedobitek, G., Klein, E., Stein, H., Fleischer, B. (1990) The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J. Immunol. 114, 2908-2914.
7. Fleischer, B. (1994) CD26: a surface protease involved in T-cell activation. Immunol. Today 15, 180-184.
8. Kähne, T., Lendecke, U., Wrenger, S., Neuber, K., Ansorge, S., Reinhold, D. (1999) Dipetidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth. Int. J. Mol. Med. 4, 3-15.
9. Oravecz, T., Pall, M., Roderiques, G., Gorrell, M. D., Ditto, M., Nguyen, N. Y., Boykins, R., Unsworth, E., Norcross, M. A. (1997) Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J. Exp. Med. 18, 1865-1872.
10. Proost, P., De Meester, I., Scholz, D., Struyf, S., Lambeir, A. M., Wuyts, A., Opdenakker, G., De Clerq, E., Scharpe, S., Van Damme, J. (1998) Aminoterminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV infection. J. Biol. Chem. 273, 7222-7227.
11. Shioda, T., Kato, H., Ohnishi, Y., Tashiro, K., Ikegawa, M., Nakayama, E. E., Hu, H., Kato, A., Sakai, Y., Liu, H., Honjo, T., Nomot, A., Iwamoto, A., Morimoto, C., Nagai, Y. (1998) Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc. Natl. Acad. Sci. USA 95, 6331-6336.
12. Proost, P., Struyf, S., Schols, D., Opdenakker, G., Sozzani, S., Allavena, P., Mantovani, A., Augustyns, K., Bal, G., Haemers, A., Lambeir, A. M., Scharpe, S., Van Damme, J., De Meester, I. (1999) Truncation of macrophage-derived chemokine by CD26/dipeptidyl peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J. Biol. Chem. 274, 3988-3993.
13. 2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J. Immunol. 161, 2672-2675.
14. Struyf, S., Proost, P., Schols, D., De Clerq, E., Opdenakker, G., Lenaerts, J-P., Detheux, M., Parmentier, M., De Meester, I., Scharpé, S., Van Damme, J. (1999) CD26/Dipeptidyl-peptidae IV down regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J. Immunol. 162, 4903-4909.
15. Proost, P., Menten, P., Struyf, S., Schutyser, E., De Meester, I., Van Damme, J. (2000) Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78β into a most efficient monocyte attractant and CCR1 agonist. Blood 96, 1674-1680.
16. Cole, K. E., Strick, C. A., Paradis, T. J., Ogborne, K. T., Loetscher, M., Gladue, R. P., Lin, W., Boyd, J. G., Moser, B., Wood, D. E., Sahagan, B. G., Neote, K. (1998) Interferon-inducible T cell alpha chemoattractant (1-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J. Exp. Med. 187, 2009-2021.
17. Loetscher, M., Gerber, B., Loetscher, P., Jones, S. A., Piali, L., Clark-Lewis, I., Baggiolini, M., Moser, B. (1996) Chemokine receptor specific for IP10 and Mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184, 963-969.
18. Qin, S., Rottman, J. B., Myers, P., Kassam, N., Weinblatt, M., Loetscher, M., Koch, A. E., Moser, B., Mackay, C. R. (1998) The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Investig. 101, 746-754.
19. Mach, F., Sauty, A., Iarossi, A. S., Sukhova, G. K., Neote, K., Libby, P., Luster, A. D. (1999) Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J. Clin. Investig. 104, 1041-1050.
20. Sorensen, T. L., Tani, M., Jensen, J., Pierce, V., Lucchinetti, C., Folcik, V. A., Qin, S., Rottman, J., Sellebjerg, F., Strieter, R. M., Frederiksen, J. L., Ransohoff, R. M. (1999) Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Investig. 103, 807-815.
21. Hancock, W. W., Lu, B., Gao, W., Csizmadia, V., Faia, K., King, J. A., Smiley, S. T., Ling, M., Gerard, N. P., Gerard, C. (2000) Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J. Exp. Med. 192, 1515-1520.
22. Püschel, G., Mentlein, R., Heymann, E. (1982) Isolation and characterization of dipeptidyl peptidase IV from human placenta. Eur. J. Biochem. 126, 359-365.
23. Nausch, I., Mentlein, R., Heymann, E. (1990) The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta. Biol. Chem. Hoppe-Seyler 371, 1113-1118.
24. Scheel-Toellner, D., Richter, E., Toellner, K-M., Reiling, N., Wacker, H-H., Flad, H-D., Gerdes, J. (1995) CD 26 expression in leprosy and other granulomatous diseases correlates with the production of interferon-γ. Lab. Investig. 73, 685-690.
25. Mentlein, R., Lucius, R. (1997). Methods for the investigation of neuropeptide catabolism and stability in vitro. Brain Res. Protoc. 1, 237-246.
26. + CXC chemokine platelet basic protein. Blood 96, 2965-2972.
27. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440-3450.
28. Petersen, F., Flad, H-D., Brandt, E. (1994) Neutrophil-activating peptides NAP-2 and IL-8 bind to the same sites on neutrophils but interact in different ways. Discrepancies in binding affinities, receptor densities, and biologic effects. J. Immunol. 152, 2467-2478.
29. Huhn, J., Ehrlich, S., Fleischer, B., von Bonin, A. (2000) Molecular analysis of CD26-mediated signal transduction in T cells. Immunol. Lett. 72, 127-132.
30. Richard, E., Arredondo-Vega, F. X., Santisteban, I., Kelly, S. J., Patel, D. D., Hershfield, M. S. (2000) The binding site of human adenosine deaminase for CD26/dipeptidyl peptidase IV: the Arg142Gln mutation impairs binding to CD26 but does not cause immune deficiency. J. Exp. Med. 192, 1223-1236.
31. Mentlein, R., Dahms, P., Grandt, D., Krüger, R. (1993) Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul. Pept. 49, 133-144.
32. Mentlein, R., Gallwitz, B., Schmidt, W. E. (1993) Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214, 829-835.
33. Härter, L., Petersen, F., Flad, H-D., Brandt, E. (1994) Connective tissueactivating peptide III desensitizes chemokine receptors on neutrophils. Requirement for proteolytic formation of the neutrophil-activating peptide 2. J. Immunol. 153, 5698-5708.
34. Pederson, R. A., White, H. A., Schlenzig, D., Pauly, R. P., McIntosh, C. S., Demuth, H-U. (1998) Improved tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47, 1253-1258.
35. Marguet, D., Baggio, L., Kobayashi, T., Bernard, A. M., Pierres, M., Nielsen, P. F., Ribel, U., Watanabe, T., Drucker, D. J., Wagtmann, N. (2000) Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA 97, 6874-6879.
36. Tsuji, E., Misumi, Y., Fujiwara, T., Takami, N., Ogata, S., Ikehara, Y. (1992) An active-site mutation (Gly633→Arg) of dipeptidyl peptidase IV causes its retention and rapid degradation in the endoplasmic reticulum. Biochemistry 31, 11921-11927.